The use of these is currently considered a fruitful strategy to combat cancer, being mainly divided according to selectivity into three generic classes: pan-PI3K inhibitors, selective isoform PI3K inhibitors, and dual PI3K/mTOR inhibitors [3,14,15]. Here, PIK3CB is linked to cancer.